Ashwani Verma
Stock Analyst at UBS
(4.20)
# 468
Out of 5,090 analysts
98
Total ratings
61.43%
Success rate
12%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Downgrades: Neutral | $26 → $11 | $9.55 | +15.18% | 5 | Nov 26, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $163 → $188 | $169.70 | +10.78% | 7 | Nov 24, 2025 | |
| ALVO Alvotech | Maintains: Buy | $13 → $10 | $5.47 | +82.82% | 1 | Nov 18, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $195 → $220 | $226.08 | -2.69% | 1 | Nov 7, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $580 → $600 | $489.31 | +22.62% | 10 | Nov 6, 2025 | |
| EXEL Exelixis | Maintains: Neutral | $35 → $40 | $44.36 | -9.83% | 5 | Nov 6, 2025 | |
| AVDL Avadel Pharmaceuticals | Downgrades: Neutral | $20 | $21.34 | -6.28% | 4 | Oct 28, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $50 → $43 | $39.83 | +7.96% | 3 | Oct 15, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $188 → $195 | $155.51 | +25.39% | 10 | Oct 9, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $23 → $26 | $28.46 | -8.64% | 10 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $39 | $27.44 | +42.13% | 8 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $133 → $144 | $149.22 | -3.50% | 5 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $18 | $22.84 | -21.19% | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $54 | $28.13 | +91.97% | 3 | Jul 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $33 → $42 | $29.52 | +42.28% | 5 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $61 | $102.52 | -40.50% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $47 → $41 | $65.67 | -37.57% | 5 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $1.05 | $1.20 | -12.50% | 5 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $114 | $69.56 | +63.89% | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 | $39.73 | -29.52% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $181.79 | -96.15% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $10.93 | +9.79% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $1.59 | +843.40% | 1 | Oct 11, 2022 |
Biohaven
Nov 26, 2025
Downgrades: Neutral
Price Target: $26 → $11
Current: $9.55
Upside: +15.18%
Jazz Pharmaceuticals
Nov 24, 2025
Downgrades: Neutral
Price Target: $163 → $188
Current: $169.70
Upside: +10.78%
Alvotech
Nov 18, 2025
Maintains: Buy
Price Target: $13 → $10
Current: $5.47
Upside: +82.82%
AbbVie
Nov 7, 2025
Maintains: Neutral
Price Target: $195 → $220
Current: $226.08
Upside: -2.69%
United Therapeutics
Nov 6, 2025
Maintains: Buy
Price Target: $580 → $600
Current: $489.31
Upside: +22.62%
Exelixis
Nov 6, 2025
Maintains: Neutral
Price Target: $35 → $40
Current: $44.36
Upside: -9.83%
Avadel Pharmaceuticals
Oct 28, 2025
Downgrades: Neutral
Price Target: $20
Current: $21.34
Upside: -6.28%
Harmony Biosciences Holdings
Oct 15, 2025
Maintains: Buy
Price Target: $50 → $43
Current: $39.83
Upside: +7.96%
Neurocrine Biosciences
Oct 9, 2025
Maintains: Buy
Price Target: $188 → $195
Current: $155.51
Upside: +25.39%
Teva Pharmaceutical Industries
Sep 24, 2025
Maintains: Buy
Price Target: $23 → $26
Current: $28.46
Upside: -8.64%
Sep 9, 2025
Maintains: Buy
Price Target: $36 → $39
Current: $27.44
Upside: +42.13%
Aug 6, 2025
Maintains: Buy
Price Target: $133 → $144
Current: $149.22
Upside: -3.50%
Jul 28, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $22.84
Upside: -21.19%
Jul 2, 2025
Maintains: Buy
Price Target: $60 → $54
Current: $28.13
Upside: +91.97%
Jun 17, 2025
Upgrades: Buy
Price Target: $33 → $42
Current: $29.52
Upside: +42.28%
Jun 3, 2025
Maintains: Neutral
Price Target: $61
Current: $102.52
Upside: -40.50%
May 2, 2025
Maintains: Neutral
Price Target: $47 → $41
Current: $65.67
Upside: -37.57%
Apr 24, 2025
Maintains: Neutral
Price Target: $1.5 → $1.05
Current: $1.20
Upside: -12.50%
Dec 10, 2024
Maintains: Buy
Price Target: $106 → $114
Current: $69.56
Upside: +63.89%
Jun 3, 2024
Downgrades: Neutral
Price Target: $28
Current: $39.73
Upside: -29.52%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $181.79
Upside: -96.15%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $10.93
Upside: +9.79%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $1.59
Upside: +843.40%